HYDM1
MCID: HYD046
MIFTS: 57

Hydatidiform Mole, Recurrent, 1 (HYDM1)

Categories: Cancer diseases, Fetal diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Hydatidiform Mole, Recurrent, 1

MalaCards integrated aliases for Hydatidiform Mole, Recurrent, 1:

Name: Hydatidiform Mole, Recurrent, 1 58 76 74
Hydatidiform Mole 58 77 54 60 76 30 13 56 6 17 74
Gestational Trophoblastic Disease 58 77 76 56 74
Complete Hydatidiform Mole 60 76 74
Hydm 58 54 76
Molar Pregnancy 54 60
Hydm1 58 76
Chm 58 76
Mole, Hydatidiform, Recurrent, Type 1 41
Gestational Trophoblastic Neoplasms 74
Hydatidiform Mole, Complete; Chm 58
Hydatidiform Mole, Recurrent, 2 74
Hydatidiform Mole, Complete 58
Complete Molar Pregnancy 60
Hydatidiform Mole; Hydm 58
Hydatid Mole 54

Characteristics:

Orphanet epidemiological data:

60
complete hydatidiform mole
Inheritance: Autosomal recessive,Not applicable; Age of onset: Adult; Age of death: normal life expectancy;
hydatidiform mole
Inheritance: Autosomal recessive,Not applicable; Age of onset: Adult; Age of death: normal life expectancy;

OMIM:

58
Inheritance:
autosomal recessive


HPO:

33
hydatidiform mole, recurrent, 1:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 58 231090
MeSH 45 D006828
ICD10 34 O01
MESH via Orphanet 46 D006828
ICD10 via Orphanet 35 O01.0 O01.1 O01.9
UMLS via Orphanet 75 C0020217 C0678213

Summaries for Hydatidiform Mole, Recurrent, 1

OMIM : 58 A hydatidiform mole is an abnormal pregnancy characterized by hydropic placental villi, trophoblastic hyperplasia, and poor fetal development. Familial recurrent hydatidiform mole is an autosomal recessive condition in which women experience recurrent pregnancy losses, predominantly complete hydatidiform mole (CHM). However, unlike sporadic CHMs, which are androgenetic with 2 paternal chromosome complements, CHMs associated with familial recurrence are genetically biparental in origin with both a maternal and a paternal contribution to the genome. Other pregnancy losses in this condition include partial hydatidiform mole, stillbirths, ectopic pregnancies, early neonatal deaths, and miscarriages, some of which may be undiagnosed molar pregnancies. Normal pregnancies are extremely rare in families with this condition (summary by Fallahian et al., 2013). (231090)

MalaCards based summary : Hydatidiform Mole, Recurrent, 1, also known as hydatidiform mole, is related to partial hydatidiform mole and placental site trophoblastic tumor. An important gene associated with Hydatidiform Mole, Recurrent, 1 is NLRP7 (NLR Family Pyrin Domain Containing 7), and among its related pathways/superpathways are Peptide hormone metabolism and Primary Focal Segmental Glomerulosclerosis FSGS. The drugs Nitroglycerin and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include placenta, uterus and lung, and related phenotypes are nausea and vomiting and anemia

NIH Rare Diseases : 54 Molar pregnancy is a condition in which the placenta does not develop properly. The symptoms of molar pregnancy, which may include vaginal bleeding, severe morning sickness, stomach cramps, and high blood pressure, typically begin around the 10th week of pregnancy. Because the embryo does not form or is malformed in molar pregnancies, and because there is a small risk of developing a cancer called choriocarcinoma, a D&C is usually performed.

UniProtKB/Swiss-Prot : 76 Hydatidiform mole, recurrent, 1: A disorder characterized by excessive trophoblast development that produces a growing mass of tissue inside the uterus at the beginning of a pregnancy. It leads to abnormal pregnancies with no embryo, and cystic degeneration of the chorionic villi.

Wikipedia : 77 Gestational trophoblastic disease (GTD) is a term used for a group of pregnancy-related tumours. These... more...

Related Diseases for Hydatidiform Mole, Recurrent, 1

Diseases in the Recurrent Hydatidiform Mole family:

Hydatidiform Mole, Recurrent, 1 Hydatidiform Mole, Recurrent, 2
Hydatidiform Mole, Recurrent, 3 Hydatidiform Mole, Recurrent, 4

Diseases related to Hydatidiform Mole, Recurrent, 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 129)
# Related Disease Score Top Affiliating Genes
1 partial hydatidiform mole 34.8 KHDC3L NLRP7
2 placental site trophoblastic tumor 32.1 CGB3 CGB5 INHA
3 gestational trophoblastic neoplasm 31.4 CDKN1C H19 KHDC3L NLRP7 PHLDA2
4 choriocarcinoma 31.1 CGA CGB3 CGB5 H19
5 triploidy 30.9 CGA KHDC3L NLRP7
6 ectopic pregnancy 30.7 CGA CGB3 CGB5
7 chromosomal triplication 30.7 CGA CGB3
8 epithelioid trophoblastic tumor 30.3 CGB3 INHA
9 mixed germ cell tumor 29.9 CGA CGB3
10 testicular cancer 29.7 CGA CGB3 CGB5
11 teratoma 29.3 CGA CGB3
12 trophoblastic neoplasm 29.2 CDKN1C CGA H19 INHA KHDC3L NLRP7
13 recurrent hydatidiform mole 12.9
14 invasive mole 12.2
15 gestational trophoblastic tumor 12.0
16 pulmonary arterio-veinous fistula 11.2
17 hydatidiform mole, recurrent, 2 11.1
18 hydatidiform mole, recurrent, 4 11.1
19 hydatidiform mole, recurrent, 3 11.1
20 hyperthyroidism, familial gestational 11.1
21 eclampsia 10.8
22 hyperthyroidism 10.7
23 pre-eclampsia 10.6
24 placenta praevia 10.5
25 severe pre-eclampsia 10.5
26 pemphigoid gestationis 10.5
27 gestational choriocarcinoma 10.5
28 choroideremia 10.4
29 graves disease 1 10.3
30 infertility 10.3
31 preeclampsia/eclampsia 1 10.3
32 anencephaly 10.3
33 ovarian hyperstimulation syndrome 10.3
34 joint disorders 10.3
35 leukemia 10.3
36 pemphigus gestationis 10.3
37 thrombosis 10.3
38 endometritis 10.3
39 sarcoma 10.3
40 endometriosis of ovary 10.3
41 nephrotic syndrome 10.3
42 ulceration of vulva 10.3
43 acromegaly 10.3
44 endometriosis 10.3
45 pulmonary tuberculosis 10.3
46 arthropathy 10.3
47 dysgerminoma 10.3
48 placenta accreta 10.3
49 ovarian cyst 10.3
50 adenoma 10.3

Graphical network of the top 20 diseases related to Hydatidiform Mole, Recurrent, 1:



Diseases related to Hydatidiform Mole, Recurrent, 1

Symptoms & Phenotypes for Hydatidiform Mole, Recurrent, 1

Human phenotypes related to Hydatidiform Mole, Recurrent, 1:

60 33 (show all 9)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nausea and vomiting 60 33 hallmark (90%) Very frequent (99-80%) HP:0002017
2 anemia 60 33 hallmark (90%) Very frequent (99-80%) HP:0001903
3 preeclampsia 60 33 hallmark (90%) Very frequent (99-80%) HP:0100602
4 spontaneous abortion 60 33 hallmark (90%) Very frequent (99-80%) HP:0005268
5 menometrorrhagia 60 33 hallmark (90%) Very frequent (99-80%) HP:0400008
6 enlarged uterus 60 33 hallmark (90%) Very frequent (99-80%) HP:0100878
7 hyperthyroidism 60 33 occasional (7.5%) Occasional (29-5%) HP:0000836
8 abnormality of the genitourinary system 33 HP:0000119
9 hydatidiform mole 33 HP:0032192

Symptoms via clinical synopsis from OMIM:

58
Prenatal Manifestations Placenta And Umbilical Cord:
gestational trophoblastic disease
hydatidiform mole

Clinical features from OMIM:

231090

MGI Mouse Phenotypes related to Hydatidiform Mole, Recurrent, 1:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 reproductive system MP:0005389 9.1 C11orf80 CGA INHA KHDC3L MEI1 PCNA

Drugs & Therapeutics for Hydatidiform Mole, Recurrent, 1

Drugs for Hydatidiform Mole, Recurrent, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitroglycerin Approved, Investigational Phase 4,Phase 2,Not Applicable 55-63-0 4510
2 Vaccines Phase 4,Phase 3
3 Immunologic Factors Phase 4,Phase 3,Phase 2
4
Methotrexate Approved Phase 3,Phase 2,Not Applicable 1959-05-2, 59-05-2 126941
5
leucovorin Approved Phase 3,Phase 2,Not Applicable 58-05-9 143 6006
6
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
7
Amifostine Approved, Investigational Phase 3 20537-88-6 2141
8
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Not Applicable 59-30-3 6037
10
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
11 Liver Extracts Phase 3
12 Vitamins Phase 3,Phase 2,Not Applicable
13 Dermatologic Agents Phase 3,Phase 2
14 Vitamin B Complex Phase 3,Phase 2,Not Applicable
15 Vitamin B9 Phase 3,Phase 2,Not Applicable
16 Trace Elements Phase 3,Phase 2,Not Applicable
17 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
18 Antimetabolites, Antineoplastic Phase 3,Phase 2
19 Hematinics Phase 3,Phase 2,Not Applicable
20 Antirheumatic Agents Phase 3,Phase 2,Not Applicable
21 Antimetabolites Phase 3,Phase 2
22 Micronutrients Phase 3,Phase 2,Not Applicable
23 Folate Phase 3,Phase 2,Not Applicable
24 Immunosuppressive Agents Phase 3,Phase 2
25 Nutrients Phase 3,Phase 2,Not Applicable
26 Folic Acid Antagonists Phase 3,Phase 2
27 Anti-Bacterial Agents Phase 3
28 Anti-Infective Agents Phase 3
29 Antibiotics, Antitubercular Phase 3
30 Radiation-Protective Agents Phase 3
31 Protective Agents Phase 3,Phase 2
32 Bone Density Conservation Agents Phase 3,Phase 2
33 Antidotes Phase 3,Phase 2
34 Hormones Phase 3
35 Calcium, Dietary Phase 3
36
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556
37
Dihydrotachysterol Approved Phase 2 67-96-9 5311071 5281010
38
Ipilimumab Approved Phase 2 477202-00-9
39
nivolumab Approved Phase 2 946414-94-4
40 Antibodies, Monoclonal Phase 2
41 Immunoglobulins Phase 2
42 Antibodies Phase 2
43 Antineoplastic Agents, Immunological Phase 2
44
Aspirin Approved, Vet_approved Not Applicable 50-78-2 2244
45
Misoprostol Approved Not Applicable 59122-46-2 5282381
46 Chorionic Gonadotropin ,Not Applicable
47 Antipyretics Not Applicable
48 Platelet Aggregation Inhibitors Not Applicable
49 Analgesics Not Applicable
50 Anti-Inflammatory Agents Not Applicable

Interventional clinical trials:

(show all 26)
# Name Status NCT ID Phase Drugs
1 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents Completed NCT00534638 Phase 4
2 A Comparison of Single Versus Double Evacuation for Treatment of Hydatidiform Mole Recruiting NCT01630954 Phase 4
3 RCT on the Efficacy of Methotrexate for the Prevention of GTD Completed NCT01984099 Phase 3 Methotrexate;Vitamin B Complex
4 Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia Completed NCT00003702 Phase 3 Methotrexate
5 Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer Completed NCT00058071 Phase 3 amifostine trihydrate
6 The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study Completed NCT01249365 Phase 3
7 Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects Completed NCT00779766 Phase 3
8 Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18 Completed NCT00122681 Phase 3
9 Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia Active, not recruiting NCT01535053 Phase 3 Leucovorin Calcium;Methotrexate
10 Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia Active, not recruiting NCT01823315 Phase 3 MTX 1;MTX 2
11 Rescue Regimen and High Dose Methotrexate in Management of Presistent Gestational Trophoplastic Neoplasia Not yet recruiting NCT03280979 Phase 2, Phase 3 rescue regimen;high dose methotrxate
12 Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors Completed NCT00521118 Phase 2
13 A Trial for Patients With Gestational Trophoblastic Disease Completed NCT00190918 Phase 2 Pemetrexed
14 Avelumab in Chemo-resistant Gestational Trophoblastic Neoplasias Recruiting NCT03135769 Phase 2 Avelumab administration at 10mg/kg
15 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
16 Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Low-Risk Gestational Trophoblastic Tumor After a Molar Pregnancy Terminated NCT00096187 Phase 2 pemetrexed disodium
17 Conformation of Beta Human Chorionic Gonadotropin During Chemotherapy for Choriocarcinoma Unknown status NCT00294177
18 The Effects of Aspirin in Gestation and Reproduction Completed NCT00467363 Not Applicable acetylsalicylic-acid (aspirin)
19 Study of the Genetic and Epigenetic Causes of Recurrent Hydatidiform Moles Recruiting NCT01008501
20 Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule Recruiting NCT03785574 Not Applicable chemotherapy
21 The French National Reference Centre of GTD Recruiting NCT02892877
22 Yervoy Pregnancy Surveillance Study Recruiting NCT02854488 Yervoy
23 BioThrax® (Anthrax) Vaccine in Pregnancy Registry Active, not recruiting NCT01653392
24 Chemoresistance of Trophoblastic Tumors Not yet recruiting NCT03488901
25 Fertility and Obstetric Outcomes After Medical Management Versus Surgical Treatment for First-trimester Miscarriage First-trimester Miscarriage Not yet recruiting NCT03570307 Not Applicable
26 Flucelvax Pregnancy Registry Withdrawn NCT02258178

Search NIH Clinical Center for Hydatidiform Mole, Recurrent, 1

Genetic Tests for Hydatidiform Mole, Recurrent, 1

Genetic tests related to Hydatidiform Mole, Recurrent, 1:

# Genetic test Affiliating Genes
1 Hydatidiform Mole 30 NLRP7

Anatomical Context for Hydatidiform Mole, Recurrent, 1

MalaCards organs/tissues related to Hydatidiform Mole, Recurrent, 1:

42
Placenta, Uterus, Lung, Thyroid, Testes, Liver, Bone

Publications for Hydatidiform Mole, Recurrent, 1

Articles related to Hydatidiform Mole, Recurrent, 1:

(show top 50) (show all 1270)
# Title Authors Year
1
Interstitial pregnancy mimicking an invasive hydatidiform mole. ( 31079718 )
2019
2
Tubal hydatidiform mole treated with salpingotomy: A case report. ( 30997056 )
2019
3
miR-196b inhibits cell migration and invasion through targeting MAP3K1 in hydatidiform mole. ( 30889489 )
2019
4
The potential value of red blood cell distribution width in patients with invasive hydatidiform mole. ( 30883924 )
2019
5
The management of hydatidiform mole with lung nodule: a retrospective analysis in 53 patients. ( 30740949 )
2019
6
Do we need post-pregnancy screening with human chorionic gonadotrophin after previous hydatidiform mole to identify patients with recurrent gestational trophoblastic disease? ( 30684876 )
2019
7
Correction to: ''Bunch of grapes'' in complete hydatidiform mole. ( 30284604 )
2019
8
A Novel Mutation in NLRP7 Related to Recurrent Hydatidiform Mole and Reproductive Failure. ( 31037924 )
2019
9
Hysteroscopic Management of Partial Hydatidiform Mole: A Novel Approach to an Old Disease. ( 29631009 )
2019
10
Genetically Related Choriocarcinoma Developing 5 Yr After a Complete Hydatidiform Mole and Simulating a Cornual Ectopic Pregnancy. ( 31033803 )
2019
11
Ultrasound and MRI Findings of Twin Pregnancies with Complete Hydatidiform Mole and Coexisting Normal Fetus: Two Case Reports. ( 30282891 )
2018
12
Hydatidiform mole: validity of the registration in the Danish National Patient Registry, the Danish Cancer Registry, and the Danish Pathology Registry 1999-2009. ( 30271218 )
2018
13
Multiple metastatic gestational trophoblastic disease after a twin pregnancy with complete hydatidiform mole and coexisting fetus, following assisted reproductive technology: Case report and literature review. ( 30122584 )
2018
14
p57KIP2 immunostaining for diagnosis of hydatidiform mole. ( 29904999 )
2018
15
Invasive hydatidiform mole in the cervix. ( 29875909 )
2018
16
Prevalence and Factors Associated with Hydatidiform Mole among Patients Undergoing Uterine Evacuation at Mbarara Regional Referral Hospital. ( 29805452 )
2018
17
Accuracy of p57KIP2 compared with genotyping to diagnose complete hydatidiform mole: a systematic review and meta-analysis. ( 29782064 )
2018
18
Recurrent complete hydatidiform mole: where we are, is there a safe gestational horizon? Opinion and mini-review. ( 29737470 )
2018
19
A 34-Week Size Uterus with a Complete Hydatidiform Mole: Hook Effect and Severe Anemia with No Vaginal Bleeding. ( 29670785 )
2018
20
Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia? ( 29477553 )
2018
21
Temporal trends in incidence and outcome of hydatidiform mole: a retrospective cohort study. ( 29451409 )
2018
22
A fetus coexisting with a complete hydatidiform mole with trisomy 9 of maternal origin. ( 29436108 )
2018
23
New insights in the pathophysiology of complete hydatidiform mole. ( 29405964 )
2018
24
DNA Genotyping of Nonmolar Donor Egg Pregnancies With Abnormal Villous Morphology: Allele Zygosity Patterns Prevent Misinterpretation as Complete Hydatidiform Mole. ( 28463912 )
2018
25
Clinical and genetic-epignetic aspects of recurrent hydatidiform mole: A review of literature. ( 29458875 )
2018
26
HCG-induced hyperthyroidism in a 51-year-old patient with hydatidiform mole. ( 30562809 )
2018
27
Choriocarcinoma with multiple lung metastases from complete hydatidiform mole with coexistent fetus during pregnancy. ( 29845692 )
2018
28
Unusual twin pregnancy: complete hydatidiform mole with coexistent normal fetus. ( 29949305 )
2017
29
May supplementation of coenzyme Q10 help prevent development of hydatidiform mole?. ( 29949281 )
2017
30
A twin pregnancy with a hydatidiform mole and a coexisting live fetus: prenatal diagnosis, treatment, and follow-up. ( 29375907 )
2017
31
Comparison of different therapeutic strategies for complete hydatidiform mole in women at least 40 years old: a retrospective cohort study. ( 29121880 )
2017
32
Whole-exome sequencing reveals genetic variants in ERC1 and KCNG4 associated with complete hydatidiform mole in Chinese Han women. ( 29088863 )
2017
33
Risk Factors for Hydatidiform Mole: Is Husband’s Job a Major Risk Factor? ( 29072060 )
2017
34
Challenges in the Routine Praxis Diagnosis of Hydatidiform Mole: a Tertiary Health Center Experience. ( 28974845 )
2017
35
An unexpected invasive hydatidiform mole in a rudimentary uterine horn: A case report. ( 28927039 )
2017
36
Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. ( 28892119 )
2017
37
Heterotopic Pregnancy Including Intrauterine Normal Gestation and Tubal Complete Hydatidiform Mole: A Case Report and Review of the Literature. ( 28800576 )
2017
38
18F-FDG PET/CT Demonstrating Chorioadenoma Destruens After Evacuation of Complete Hydatidiform Mole. ( 28759528 )
2017
39
Molecular Diagnosis of Placental Hydatidiform Mole: Innovation and Outcomes. ( 28757408 )
2017
40
Establishment and characterization of cell lines derived from complete hydatidiform mole. ( 28713902 )
2017
41
Uterine artery Doppler flow velocimetry parameters for predicting gestational trophoblastic neoplasia after complete hydatidiform mole, a prospective cohort study. ( 28591340 )
2017
42
F10, a novel hydatidiform mole-associated gene, inhibits the paclitaxel sensitivity of A549 lung cancer cells by downregulating BAX and caspase-3. ( 28454434 )
2017
43
Complete hydatidiform mole with co-existing fetus: Predictors of live birth. ( 28301807 )
2017
44
HDLive Silhouette Inversion Mode in Diagnosis of Complete Hydatidiform Mole. ( 28133778 )
2017
45
Role of Surgery in the Management of Hydatidiform Mole in Elderly Patients: A Single-Center Clinical Experience. ( 28129241 )
2017
46
"Bunch of grapes" in complete hydatidiform mole. ( 27933479 )
2017
47
Prenatal Diagnosis of Twin Pregnancies with Complete Hydatidiform Mole and Coexistent Normal Fetus: A Series of 13 Cases. ( 27522447 )
2017
48
Partial hydatidiform mole in a phenylketonuria patient treated with sapropterin dihydrochloride. ( 27898272 )
2017
49
miR-21 Is Overexpressed in Hydatidiform Mole Tissues and Promotes Proliferation, Migration, and Invasion in Choriocarcinoma Cells. ( 27922982 )
2017
50
The hydatidiform mole. ( 26421650 )
2016

Variations for Hydatidiform Mole, Recurrent, 1

UniProtKB/Swiss-Prot genetic disease variations for Hydatidiform Mole, Recurrent, 1:

76
# Symbol AA change Variation ID SNP ID
1 NLRP7 p.Arg693Pro VAR_026711 rs104895502
2 NLRP7 p.Arg693Trp VAR_026712 rs104895506
3 NLRP7 p.Asn913Ser VAR_026713 rs104895503
4 NLRP7 p.Leu398Arg VAR_059035 rs104895548
5 NLRP7 p.Pro651Ser VAR_059036 rs104895549
6 NLRP7 p.Arg693Gln VAR_059037 rs104895502
7 NLRP7 p.Pro716Ala VAR_059038 rs104895550
8 NLRP7 p.Arg721Trp VAR_059039 rs104895525
9 NLRP7 p.Cys761Tyr VAR_059040 rs104895552

ClinVar genetic disease variations for Hydatidiform Mole, Recurrent, 1:

6 (show top 50) (show all 310)
# Gene Variation Type Significance SNP ID Assembly Location
1 NLRP7 NM_001127255.1(NLRP7): c.2891T> C (p.Leu964Pro) single nucleotide variant not provided rs104895523 GRCh37 Chromosome 19, 55439063: 55439063
2 NLRP7 NM_001127255.1(NLRP7): c.2891T> C (p.Leu964Pro) single nucleotide variant not provided rs104895523 GRCh38 Chromosome 19, 54927695: 54927695
3 NLRP7 NM_001127255.1(NLRP7): c.295G> T (p.Glu99Ter) single nucleotide variant not provided rs104895507 GRCh37 Chromosome 19, 55452356: 55452356
4 NLRP7 NM_001127255.1(NLRP7): c.295G> T (p.Glu99Ter) single nucleotide variant not provided rs104895507 GRCh38 Chromosome 19, 54940988: 54940988
5 NLRP7 NM_001127255.1(NLRP7): c.2981+123T> C single nucleotide variant not provided rs269932 GRCh37 Chromosome 19, 55438850: 55438850
6 NLRP7 NM_001127255.1(NLRP7): c.2981+123T> C single nucleotide variant not provided rs269932 GRCh38 Chromosome 19, 54927482: 54927482
7 NLRP7 NM_001127255.1(NLRP7): c.2981+142C> A single nucleotide variant not provided rs269931 GRCh37 Chromosome 19, 55438831: 55438831
8 NLRP7 NM_001127255.1(NLRP7): c.2981+142C> A single nucleotide variant not provided rs269931 GRCh38 Chromosome 19, 54927463: 54927463
9 NLRP7 NM_001127255.1(NLRP7): c.2981+29_2981+32delGTTT deletion not provided rs104895515 GRCh37 Chromosome 19, 55438941: 55438944
10 NLRP7 NM_001127255.1(NLRP7): c.2981+29_2981+32delGTTT deletion not provided rs104895515 GRCh38 Chromosome 19, 54927573: 54927576
11 NLRP7 NM_206828.3(NLRP7): c.352+13G> A single nucleotide variant Uncertain significance rs115894800 GRCh37 Chromosome 19, 55452286: 55452286
12 NLRP7 NM_206828.3(NLRP7): c.352+13G> A single nucleotide variant Uncertain significance rs115894800 GRCh38 Chromosome 19, 54940918: 54940918
13 NLRP7 NM_206828.3(NLRP7): c.555C> T (p.Thr185=) single nucleotide variant Uncertain significance rs754428027 GRCh37 Chromosome 19, 55451632: 55451632
14 NLRP7 NM_206828.3(NLRP7): c.555C> T (p.Thr185=) single nucleotide variant Uncertain significance rs754428027 GRCh38 Chromosome 19, 54940264: 54940264
15 NLRP7 NM_206828.3(NLRP7): c.681C> A (p.Ile227=) single nucleotide variant Uncertain significance rs201456445 GRCh37 Chromosome 19, 55451506: 55451506
16 NLRP7 NM_206828.3(NLRP7): c.681C> A (p.Ile227=) single nucleotide variant Uncertain significance rs201456445 GRCh38 Chromosome 19, 54940138: 54940138
17 NLRP7 NM_206828.3(NLRP7): c.1104T> C (p.Ile368=) single nucleotide variant Uncertain significance rs1654636 GRCh38 Chromosome 19, 54939715: 54939715
18 NLRP7 NM_206828.3(NLRP7): c.1257C> G (p.Ala419=) single nucleotide variant Uncertain significance rs151120858 GRCh38 Chromosome 19, 54939562: 54939562
19 NLRP7 NM_206828.3(NLRP7): c.1257C> G (p.Ala419=) single nucleotide variant Uncertain significance rs151120858 GRCh37 Chromosome 19, 55450930: 55450930
20 NLRP7 NM_206828.3(NLRP7): c.2682T> C (p.Tyr894=) single nucleotide variant Benign/Likely benign rs269951 GRCh38 Chromosome 19, 54930627: 54930627
21 NLRP7 NM_206828.3(NLRP7): c.2682T> C (p.Tyr894=) single nucleotide variant Benign/Likely benign rs269951 GRCh37 Chromosome 19, 55441995: 55441995
22 NLRP7 NM_206828.3(NLRP7): c.2750G> A (p.Arg917His) single nucleotide variant Uncertain significance rs371741023 GRCh38 Chromosome 19, 54930559: 54930559
23 NLRP7 NM_206828.3(NLRP7): c.2750G> A (p.Arg917His) single nucleotide variant Uncertain significance rs371741023 GRCh37 Chromosome 19, 55441927: 55441927
24 NLRP7 NM_206828.3(NLRP7): c.2912C> T (p.Thr971Met) single nucleotide variant Uncertain significance rs144955489 GRCh38 Chromosome 19, 54923771: 54923771
25 NLRP7 NM_206828.3(NLRP7): c.2912C> T (p.Thr971Met) single nucleotide variant Uncertain significance rs144955489 GRCh37 Chromosome 19, 55435139: 55435139
26 NLRP7 NM_206828.3(NLRP7): c.*180G> C single nucleotide variant Likely benign rs775865 GRCh38 Chromosome 19, 54923560: 54923560
27 NLRP7 NM_206828.3(NLRP7): c.*180G> C single nucleotide variant Likely benign rs775865 GRCh37 Chromosome 19, 55434928: 55434928
28 NLRP7 NM_206828.3(NLRP7): c.1104T> C (p.Ile368=) single nucleotide variant Uncertain significance rs1654636 GRCh37 Chromosome 19, 55451083: 55451083
29 NLRP7 NM_206828.3(NLRP7): c.-49C> T single nucleotide variant Uncertain significance rs886054634 GRCh37 Chromosome 19, 55458846: 55458846
30 NLRP7 NM_206828.3(NLRP7): c.-49C> T single nucleotide variant Uncertain significance rs886054634 GRCh38 Chromosome 19, 54947478: 54947478
31 NLRP7 NM_206828.3(NLRP7): c.-39-3C> T single nucleotide variant Uncertain significance rs772074527 GRCh37 Chromosome 19, 55453121: 55453121
32 NLRP7 NM_206828.3(NLRP7): c.-39-3C> T single nucleotide variant Uncertain significance rs772074527 GRCh38 Chromosome 19, 54941753: 54941753
33 NLRP7 NM_206828.3(NLRP7): c.66A> G (p.Leu22=) single nucleotide variant Uncertain significance rs149175257 GRCh37 Chromosome 19, 55453014: 55453014
34 NLRP7 NM_206828.3(NLRP7): c.66A> G (p.Leu22=) single nucleotide variant Uncertain significance rs149175257 GRCh38 Chromosome 19, 54941646: 54941646
35 NLRP7 NM_206828.3(NLRP7): c.336G> C (p.Ser112=) single nucleotide variant Uncertain significance rs766338217 GRCh37 Chromosome 19, 55452315: 55452315
36 NLRP7 NM_206828.3(NLRP7): c.336G> C (p.Ser112=) single nucleotide variant Uncertain significance rs766338217 GRCh38 Chromosome 19, 54940947: 54940947
37 NLRP7 NM_206828.3(NLRP7): c.390G> A (p.Gln130=) single nucleotide variant Benign/Likely benign rs775883 GRCh37 Chromosome 19, 55451797: 55451797
38 NLRP7 NM_206828.3(NLRP7): c.390G> A (p.Gln130=) single nucleotide variant Benign/Likely benign rs775883 GRCh38 Chromosome 19, 54940429: 54940429
39 NLRP7 NM_206828.3(NLRP7): c.531C> T (p.His177=) single nucleotide variant Conflicting interpretations of pathogenicity rs746150420 GRCh37 Chromosome 19, 55451656: 55451656
40 NLRP7 NM_206828.3(NLRP7): c.531C> T (p.His177=) single nucleotide variant Conflicting interpretations of pathogenicity rs746150420 GRCh38 Chromosome 19, 54940288: 54940288
41 NLRP7 NM_206828.3(NLRP7): c.955G> A (p.Val319Ile) single nucleotide variant Benign/Likely benign rs775882 GRCh37 Chromosome 19, 55451232: 55451232
42 NLRP7 NM_206828.3(NLRP7): c.955G> A (p.Val319Ile) single nucleotide variant Benign/Likely benign rs775882 GRCh38 Chromosome 19, 54939864: 54939864
43 NLRP7 NM_206828.3(NLRP7): c.1113G> A (p.Thr371=) single nucleotide variant Uncertain significance rs531055840 GRCh37 Chromosome 19, 55451074: 55451074
44 NLRP7 NM_206828.3(NLRP7): c.1113G> A (p.Thr371=) single nucleotide variant Uncertain significance rs531055840 GRCh38 Chromosome 19, 54939706: 54939706
45 NLRP7 NM_206828.3(NLRP7): c.1491C> T (p.Ile497=) single nucleotide variant Likely benign rs775880 GRCh38 Chromosome 19, 54939328: 54939328
46 NLRP7 NM_206828.3(NLRP7): c.1491C> T (p.Ile497=) single nucleotide variant Likely benign rs775880 GRCh37 Chromosome 19, 55450696: 55450696
47 NLRP7 NM_206828.3(NLRP7): c.1548T> C (p.Ile516=) single nucleotide variant Uncertain significance rs367965993 GRCh38 Chromosome 19, 54939271: 54939271
48 NLRP7 NM_206828.3(NLRP7): c.1548T> C (p.Ile516=) single nucleotide variant Uncertain significance rs367965993 GRCh37 Chromosome 19, 55450639: 55450639
49 NLRP7 NM_206828.3(NLRP7): c.1718G> A (p.Gly573Asp) single nucleotide variant Uncertain significance rs149696586 GRCh38 Chromosome 19, 54939101: 54939101
50 NLRP7 NM_206828.3(NLRP7): c.1718G> A (p.Gly573Asp) single nucleotide variant Uncertain significance rs149696586 GRCh37 Chromosome 19, 55450469: 55450469

Expression for Hydatidiform Mole, Recurrent, 1

Search GEO for disease gene expression data for Hydatidiform Mole, Recurrent, 1.

GO Terms for Hydatidiform Mole, Recurrent, 1

Biological processes related to Hydatidiform Mole, Recurrent, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.56 CGA CGB3 CGB5 INHA
2 cell-cell signaling GO:0007267 9.5 CGB3 CGB5 INHA
3 hormone-mediated signaling pathway GO:0009755 9.37 CGB3 CGB5
4 female gamete generation GO:0007292 9.16 CGB3 CGB5
5 negative regulation of phosphorylation GO:0042326 8.96 INHA CDKN1C
6 peptide hormone processing GO:0016486 8.8 CGB5 CGB3 CGA

Molecular functions related to Hydatidiform Mole, Recurrent, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 CGA CGB3 INHA

Sources for Hydatidiform Mole, Recurrent, 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....